Objective To explore the effect of bevacizumab-containing combination regimen in patients with ovarian cancer,and to analyze the changes of CA153 and CA199 before and after treatment.Methods A total of 86 patients with ovarian cancer admitted to our hospital were selected as the research objects.According to different chemotherapy regimens,they were divided into two groups,including 40 patients who received paclitaxel+carboplatin chemotherapy were in the TC chemotherapy group,and 46 patients who were treated with bevacizumab on the basis of chemotherapy group were in the combined group.The short-term efficacy,toxicity,serological indexes and immune function of the two groups were compared.Results After 7 days,1 month and 6 months of treatment,the levels of CD3+,CD4+ and CD4+/CD8+ in the combined group were higher than those in the TC chemotherapy group(P<0.05).After 1 and 6 months of treatment,the levels of carbohydrate antigen 153(CA153),carbohydrate antigen 199(CA199)and carbohydrate antigen 125(CA125)in the combined group were lower than those in the TC chemotherapy group(P<0.05).The total effective rate and 1-year survival rate of the combined group were higher than those of the TC chemotherapy group(P<0.05).There was no significant difference in the grade of hemoglobin reduction and thrombocytopenia between the two groups(P>0.05).The proportion of grade 1-2 toxicity of leukopenia,nausea,vomiting and diarrhea in combination group was higher than those in TC chemotherapy group(P<0.05).Conclusion The combination regimen containing bevacizumab can improve immune function and serological indexes in ovarian cancer patients,which has high drug safety and the survival rate of patients within 1 year.
维普
万方数据